The options market is pricing an expected move of ±15.77% (±$0.15) for LCTX (Lineage Cell Therapeutics, Inc.) earnings on Thursday, November 5, 2026 (time not confirmed). That is the mid price of the $1.00 at-the-money straddle expiring Friday, November 20, 2026, with LCTX at $0.95 as of Oct 21, 2026 3:59 PM ET (CBOE delayed data). The nearest expiration is 15 days after the report, so this straddle also prices non-earnings movement and likely overstates the pure earnings move. Note: these option quotes are indicative only (a zero bid, very wide spread, or no strike near the price), so this figure may overstate the real expected move.
| Earnings date | Thursday, November 5, 2026 · Time not confirmed |
| Fiscal quarter | Sep/2026 |
| EPS forecast (consensus) | ($0.02) (3 estimates) |
| Market cap | $240.6M |
| Straddle bid / mid / ask | $0.00 / $0.15 / $0.30 |
| Quote quality | Indicative only — a zero bid, very wide spread, or no strike near the price |
| Expiration used | Friday, November 20, 2026 (29 days out; 15 days after the report) |
| 85% convention | ±13.40% (±$0.13). Some sites quote 0.85 × straddle as a one-standard-deviation estimate. |
| Snapshot | 2026-10-22 |
Expected vs actual history
Expected is the move options priced in before each report; actual is how far LCTX really moved after it. The beat rate is how often the actual move was bigger.
No completed reports tracked yet. History began Wednesday, October 21, 2026 and builds as companies report; after LCTX reports, its actual move and whether it beat the expected move will appear here.
Moved more than expected
—
No completed LCTX reports have been tracked yet (tracking began Wednesday, October 21, 2026), so there is no beat rate yet.
FAQ
What is the expected move for LCTX earnings?
The options market is pricing an expected move of ±15.77% (±$0.15) for LCTX (Lineage Cell Therapeutics, Inc.) earnings on Thursday, November 5, 2026 (time not confirmed). That is the mid price of the $1.00 at-the-money straddle expiring Friday, November 20, 2026, with LCTX at $0.95 as of Oct 21, 2026 3:59 PM ET (CBOE delayed data). The nearest expiration is 15 days after the report, so this straddle also prices non-earnings movement and likely overstates the pure earnings move. Note: these option quotes are indicative only (a zero bid, very wide spread, or no strike near the price), so this figure may overstate the real expected move.
When does LCTX report earnings?
Lineage Cell Therapeutics, Inc. is scheduled to report on Thursday, November 5, 2026, time not confirmed, per the Nasdaq earnings calendar. Dates can change; confirm with the company's investor relations site.
What price range does the LCTX expected move imply?
Using the $0.95 reference price and a ±$0.15 expected move, the implied range through Friday, November 20, 2026 is about $0.80 to $1.10. This is a market estimate, not a forecast.
How often does LCTX move more than expected after earnings?
No completed LCTX reports have been tracked yet (tracking began Wednesday, October 21, 2026), so there is no beat rate yet.
How is the expected move calculated?
It is the mid price (average of bid and ask) of the at-the-money call plus the at-the-money put in the first expiration that includes the post-earnings trading session, using CBOE delayed quotes. Dividing by the stock price gives the percentage.
Is this investment advice?
No. EarningsMoves publishes factual market data for information only. Quotes are delayed and may be inaccurate.